Absci Corp (ABSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Absci Corp (ABSI) has a cash flow conversion efficiency ratio of -0.119x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.03 Million) by net assets ($210.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Absci Corp - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Absci Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Absci Corp for a breakdown of total debt and financial obligations.
Absci Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Absci Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dimerco Express
TWO:5609
|
0.001x |
|
Alucon Public Company Limited
BK:ALUCON
|
0.018x |
|
Infortrend Technology Inc
TW:2495
|
-0.012x |
|
Oxiquim S.A
SN:OXIQUIM
|
0.051x |
|
RFG Holdings Ltd
JSE:RFG
|
0.121x |
|
Baiyang Aquatic Group Inc
SHE:002696
|
0.003x |
|
Invercap
SN:INVERCAP
|
0.051x |
|
Bus Online Co Ltd
SHE:002188
|
-0.085x |
Annual Cash Flow Conversion Efficiency for Absci Corp (2019–2024)
The table below shows the annual cash flow conversion efficiency of Absci Corp from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Absci Corp market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $179.13 Million | $-72.40 Million | -0.404x | -10.17% |
| 2023-12-31 | $176.18 Million | $-64.64 Million | -0.367x | -23.78% |
| 2022-12-31 | $274.41 Million | $-81.34 Million | -0.296x | -79.08% |
| 2021-12-31 | $366.11 Million | $-60.60 Million | -0.166x | -1.10% |
| 2020-12-31 | $67.00 Million | $-10.97 Million | -0.164x | -211.71% |
| 2019-12-31 | $-41.16 Million | $-6.03 Million | 0.147x | -- |
About Absci Corp
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treat… Read more